Sprint Bioscience AB AI Stock Analysis
Want to see SE:SPRINT full AI Analyst Report?
Sprint Bioscience AB (SPRINT) AI Stock Analysis
Sprint Bioscience AB
(Nasdaq OMX AB:SPRINT)
The score is driven mainly by strong financial performance—high margins, solid net income, and strong free cash flow—supported by a debt-free balance sheet. Technicals add moderate support with price above key moving averages and positive (but not overheated) momentum. Valuation is favorable due to a low P/E, though the key risk is earnings stability given historical cyclicality and slightly declining TTM revenue.
Sprint Bioscience AB (SPRINT) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 388.30M
- Dividend Yield
- ―
- Average Volume (3M)
- 282.09K
- Price to Earnings (P/E)
- 5.5
- Beta (1Y)
- 1.38
- Revenue Growth
- 170.38%
- EPS Growth
- ―
- Country
- Sweden
- Employees
- 32
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Sprint Bioscience AB Business Overview & Revenue Model
Company Description
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunoth...
Sprint Bioscience AB Financial Statement Overview
Summary
Strong turnaround with sharply positive profitability (TTM net margin ~52%) and solid earnings (~69.9m), backed by robust operating cash flow (~67.5m) and free cash flow (~66.6m) that closely tracks net income. Balance sheet is a key strength with zero debt and rebuilt equity, though results and equity levels have been volatile and TTM revenue is slightly down (~-3.8%), raising durability risk.
Income Statement
78PositiveBalance Sheet
90Very PositiveCash Flow
84Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 133.91M | 167.17M | 65.64M | 50.48M | 83.00K | 35.11M |
| Gross Profit | 116.67M | 97.33M | 37.30M | 41.79M | -60.91M | 24.68M |
| EBITDA | 73.03M | 98.40M | -17.32M | 396.00K | -60.00M | -24.49M |
| Net Income | 69.91M | 91.74M | -18.28M | -438.00K | -60.17M | -25.35M |
Balance Sheet | ||||||
| Total Assets | 89.06M | 136.66M | 42.05M | 62.38M | 37.42M | 79.14M |
| Cash, Cash Equivalents and Short-Term Investments | 77.52M | 126.70M | 25.06M | 49.93M | 29.49M | 70.64M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 13.15M | 17.48M | 32.78M | 34.60M | 9.23M | 8.68M |
| Stockholders Equity | 75.92M | 119.18M | 9.27M | 27.77M | 28.19M | 70.45M |
Cash Flow | ||||||
| Free Cash Flow | 66.59M | 83.44M | -24.65M | 20.42M | -59.05M | -42.82M |
| Operating Cash Flow | 67.48M | 83.53M | -23.36M | 22.87M | -59.05M | -40.12M |
| Investing Cash Flow | -850.00K | -54.00K | -1.30M | -2.45M | 0 | -2.71M |
| Financing Cash Flow | -61.00K | 18.17M | -225.00K | 24.00K | 17.90M | 86.39M |
Sprint Bioscience AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPRINT, the sentiment is Neutral. The current price of 3.68 is below the 20-day moving average (MA) of 3.71, above the 50-day MA of 3.47, and above the 200-day MA of 3.23, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 49.64 is Neutral, neither overbought nor oversold. The STOCH value of 36.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SPRINT.
Sprint Bioscience AB Peers Comparison
Overall Rating
SE:CANTA83Outperform
SE:SPRINT80Outperform
SE:ELIC48Neutral
SE:IMMU48Neutral
SE:BINV43Neutral
SE:IVACC38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 363.43M | 1.90 | 63.09% | ― | ― | ― | |
| 80Outperform | SEK 388.30M | 5.49 | 71.44% | ― | 170.38% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | SEK 164.51M | -6.97 | -56.09% | ― | ― | 14.10% | |
| 48Neutral | SEK 222.02M | -1.96 | -19.14% | ― | ― | 13.06% | |
| 43Neutral | SEK 137.53M | -0.28 | -128.54% | ― | -83.67% | -50.29% | |
| 38Underperform | SEK 224.94M | -2.19 | -43.10% | ― | -17.73% | 18.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:SPRINT | Sprint Bioscience AB | 3.68 | 2.24 | 155.56% | |
| SE:BINV | BioInvent International AB | 2.09 | -27.96 | -93.04% | |
| SE:ELIC | Elicera Therapeutics AB | 2.46 | -2.70 | -52.27% | |
| SE:IVACC | Intervacc AB | 0.66 | -0.24 | -26.34% | |
| SE:IMMU | Immunicum AB | 3.50 | -1.49 | -29.79% | |
| SE:CANTA | Cantargia AB | 1.29 | -1.94 | -60.03% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026